NSE JUBLPHARMA · BSE 530019 · Biotechnology & Drugs · NIFTY 500
Jubilant Pharmova Share Price
₹1,064.55
▲ +₹4.56 · 0.43%
NSE · as of 24 Sep 2026, 9:43 AM · BSE ₹1,063.20
Today's range
₹1,038.05Low₹1,067.30High
52-week range
₹783.75Low · 9 Mar 2026₹1,183.90High · 21 Oct 2025
Jubilant Pharmova Overview
Where the price stands, how it has moved and how it sits against its averages.
Jubilant Pharmova shares last traded at ₹1,064.55 on the NSE, up 0.43% on the day. That is 10.1% below the 52-week high of ₹1,183.90 and 35.8% above the 52-week low of ₹783.75. The stock trades at 43.68× earnings, above the sector average of 36.50. Its market value is ₹16,866 Cr.
Price returns
1 Day▲ +0.43%
5 Days▲ +5.54%
This month▲ +19.97%
3 Months▲ +8.76%
6 Months▲ +23.07%
This year▼ −1.43%
1 Year▼ −2.47%
Against the market: 1 Month ▲ +23.44% · 3 Months ▲ +11.90% · 6 Months ▲ +23.80% · This year ▲ +12.26% · 1 Year ▲ +7.01%
Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.
Moving averages — price is above 6 of 6
- Today's price₹1,064.55
- 5-day average₹1,040.02 ▲ price 2.4% above
- 10-day average₹1,027.97 ▲ price 3.6% above
- 100-day average₹965.03 ▲ price 10.3% above
- 20-day average₹964.88 ▲ price 10.3% above
- 300-day average₹959.98 ▲ price 10.9% above
- 50-day average₹951.93 ▲ price 11.8% above
Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.
Jubilant Pharmova Financial Results
Revenue and net profit in ₹ crore, with the full statements underneath.
8,280
898
−61
399
Year by year
| Fiscal year | Revenue | Growth | Net profit | Net margin | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2026 | ₹8,280 Cr | ▲ +14.4% | ₹399 Cr | 4.8% | ₹25.08 | ₹5.00 |
| FY 2025 | ₹7,235 Cr | ▲ +7.9% | ₹839 Cr | 11.6% | ₹52.84 | ₹5.00 |
| FY 2024 | ₹6,703 Cr | ▲ +6.7% | ₹77 Cr | 1.2% | ₹4.85 | ₹5.00 |
| FY 2023 | ₹6,282 Cr | ▲ +2.5% | −₹61 Cr | −1.0% | −₹3.83 | ₹5.00 |
| FY 2022 | ₹6,130 Cr | ▲ +0.5% | ₹414 Cr | 6.8% | ₹26.01 | ₹5.00 |
| FY 2021 | ₹6,099 Cr | ▲ +2.1% | ₹836 Cr | 13.7% | ₹36.05 | ₹5.00 |
| FY 2020 | ₹5,976 Cr | — | ₹898 Cr | 15.0% | ₹38.05 | ₹5.00 |
2,290
2,229
154
57
Quarter by quarter
| Quarter | Revenue | vs prev. qtr | Net profit | Net margin | EPS |
|---|---|---|---|---|---|
| Q1 FY27 | ₹2,229 Cr | ▼ −2.6% | ₹57 Cr | 2.5% | ₹3.56 |
| Q4 FY26 | ₹2,290 Cr | ▲ +7.9% | ₹119 Cr | 5.2% | ₹7.52 |
| Q3 FY26 | ₹2,123 Cr | ▲ +7.9% | ₹56 Cr | 2.6% | ₹3.52 |
| Q2 FY26 | ₹1,966 Cr | ▲ +3.5% | ₹120 Cr | 6.1% | ₹7.57 |
| Q1 FY26 | ₹1,901 Cr | ▼ −1.5% | ₹103 Cr | 5.4% | ₹6.47 |
| Q4 FY25 | ₹1,929 Cr | ▲ +5.9% | ₹154 Cr | 8.0% | ₹9.67 |
| Q3 FY25 | ₹1,822 Cr | ▲ +4.0% | ₹101 Cr | 5.5% | ₹6.36 |
| Q2 FY25 | ₹1,752 Cr | — | ₹103 Cr | 5.9% | ₹6.46 |
Balance sheet — FY26
Owes (liabilities)Shareholders' equity
54%
46%
- Total assets₹15,523 Cr
- Total liabilities₹8,430 Cr
- Shareholders' equity₹7,093 Cr
- Total debt₹3,615 Cr
- Cash & investments₹1,265 Cr
- Current ratio1.62×
- Revenue growth, 5 yr6.31% a year
- EPS growth, 5 yr−7.00% a year
- Operating margin (TTM)8.01%
- Net margin (TTM)4.08%
Cash flow — FY26
Operating activities
▲ ₹1,227 Cr
Investing activities
▼ −₹1,260 Cr
Financing activities
▲ ₹95 Cr
Free cash flow
▼ −₹222 Cr
Net change in cash
▲ ₹179 Cr
Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.
Full financial statements, FY20–FY26
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total revenue | 5,975.79 | 6,098.54 | 6,130.16 | 6,281.73 | 6,702.90 | 7,234.50 | 8,279.60 |
| Cost of revenue | 1,760.47 | 1,859.24 | 1,921.29 | 2,389.50 | 2,571.00 | 2,765.90 | 3,146.60 |
| Gross profit | 4,215.32 | 4,239.29 | 4,208.88 | 3,892.23 | 4,131.90 | 4,468.60 | 5,133.00 |
| Operating expenses | 4,800.38 | 5,001.09 | 5,305.71 | 6,108.72 | 6,348.70 | 6,068.20 | 7,519.40 |
| Operating income | 1,175.41 | 1,097.44 | 824.45 | 173.01 | 354.20 | 1,166.30 | 760.20 |
| Depreciation | 431.55 | 426.07 | 381.70 | 382.60 | 381.90 | 368.60 | 440.40 |
| Profit before tax | 1,012.88 | 871.08 | 630.45 | 27.78 | 170.50 | 980.60 | 614.10 |
| Tax | 406.84 | 297.22 | 217.43 | 92.66 | 97.80 | 144.30 | 216.60 |
| Net profit | 898.25 | 835.87 | 413.94 | −60.98 | 77.10 | 839.40 | 398.50 |
| EPS (₹) | 38.05 | 36.05 | 26.01 | −3.83 | 4.85 | 52.84 | 25.08 |
| Dividend per share (₹) | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total assets | 12,521.65 | 8,918.11 | 9,990.87 | 11,156.65 | 11,548.50 | 12,756.40 | 15,522.70 |
| Current assets | 5,038.35 | 2,952.50 | 3,509.19 | 3,762.40 | 3,876.10 | 3,577.20 | 4,109.30 |
| Cash & short-term investments | 1,388.28 | 661.10 | 980.26 | 1,010.78 | 953.90 | 1,086.20 | 1,265.20 |
| Inventory | 1,879.23 | 1,142.85 | 1,286.08 | 1,421.50 | 1,303.80 | 1,148.60 | 1,254.30 |
| Property, plant & equipment | 4,287.48 | 2,575.19 | 2,791.10 | 3,365.12 | 3,687.10 | 5,168.20 | 6,903.30 |
| Total liabilities | 6,917.77 | 4,176.62 | 4,672.30 | 5,757.37 | 6,114.60 | 6,501.50 | 8,429.90 |
| Current liabilities | 2,619.01 | 1,048.83 | 1,591.60 | 1,772.40 | 1,889.00 | 2,164.60 | 2,538.90 |
| Total debt | 4,808.39 | 2,829.56 | 3,192.00 | 3,676.76 | 3,664.00 | 2,731.00 | 3,614.70 |
| Total equity | 5,603.88 | 4,741.49 | 5,318.56 | 5,399.28 | 5,433.90 | 6,254.90 | 7,092.80 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| From operations | 1,542.94 | 1,707.28 | 837.54 | 660.67 | 971.30 | 1,072.10 | 1,226.80 |
| From investing | −327.00 | −739.01 | −380.37 | −544.41 | −607.90 | 487.70 | −1,260.00 |
| From financing | −1,050.37 | −1,709.39 | −32.60 | −156.68 | −432.50 | −1,452.70 | 94.90 |
| Capital expenditure | −574.15 | −527.49 | −599.99 | −814.45 | −897.70 | −1,115.60 | −1,449.10 |
| Dividends paid | −152.81 | −1.48 | −80.05 | −80.06 | −79.80 | −79.60 | −79.50 |
| Net change in cash | 225.42 | −728.86 | 481.86 | 30.10 | −57.50 | 131.90 | 178.80 |
What Analysts Say
3 analysts
Recommendations from 3 analysts who cover Jubilant Pharmova.
Buy
average rating 2.33 on a 1–5 scale
Strong buyBuyHoldSellStrong sell
▲ 2 bullish (66.7%) · 0 hold (0.0%) · ▼ 1 bearish (33.3%)
Votes
Strong Buy
1 (33%)
Buy
1 (33%)
Hold
0 (0%)
Sell
1 (33%)
Strong Sell
0 (0%)
How the votes changed
| Rating | 3M ago | 2M ago | 1M ago | 1W ago | Now | 3-month change |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | — |
| Buy | 2 | 2 | 2 | 2 | 1 | ▼ −1 |
| Hold | 0 | 0 | 0 | 0 | 0 | — |
| Sell | 1 | 1 | 1 | 1 | 1 | — |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | — |
Analyst ratings are opinions, not a guarantee of returns.
Jubilant Pharmova vs Peers
Side by side with other biotechnology & drugs companies. The small bars compare each column.
| Company | Price | Change | Market cap | P/E | P/B | ROE (5 yr) | Net margin | Div. yield | Rating |
|---|---|---|---|---|---|---|---|---|---|
| Jubilant Pharmova | ₹1,064.55 | ▲ +0.43% | ₹16,866 Cr | 43.68 | 2.36 | 5.89% | 4.08% | 0.47% | This stock |
| Sun Pharmaceutical Industries | ₹1,850.00 | ▼ −0.80% | ₹4,43,867 Cr | 38.40 | 5.55 | 14.22% | 19.12% | 0.83% | Moderately Bearish |
| Divi's Laboratories | ₹9,621.00 | ▲ +0.25% | ₹2,55,407 Cr | 73.32 | 11.48 | 16.87% | 24.32% | 0.41% | Bullish |
| Torrent Pharmaceuticals | ₹4,929.60 | ▼ −1.01% | ₹1,87,499 Cr | 72.73 | 19.22 | 23.00% | 15.29% | 0.80% | Bullish |
| Cipla | ₹1,401.10 | ▲ +1.53% | ₹1,13,189 Cr | 27.57 | 3.33 | 14.47% | 13.74% | 0.92% | Neutral |
| Zydus Lifesciences | ₹1,184.20 | ▲ +1.26% | ₹1,18,124 Cr | 21.19 | 4.24 | 17.90% | 18.51% | 0.09% | Bullish |
Rating = the data provider's overall technical view of each peer. Company names link to their own pages.
Jubilant Pharmova Key Metrics
Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.
Jubilant PharmovaBenchmarkComfortable → stretched
Valuation Is the price reasonable?
P/E (TTM)Price ÷ yearly earnings per share
43.68
▲ 20% above the sector average of 36.50
P/E, 12-month rangeLow 14.28 · high 225.10
14%
Today's P/E sits 14% of the way from its low to its high
P/BPrice ÷ book value per share
2.36
P/SPrice ÷ sales per share
1.95
P/CFPrice ÷ cash flow per share
20.41
Profitability Of every ₹100 of sales, how much is kept?
Gross marginKept after the cost of goods
67.77%
▲ above its 5-yr average of 63.05%
Operating marginKept after running costs
8.01%
▼ below its 5-yr average of 9.47%
Pre-tax marginKept before tax
6.34%
▼ below its 5-yr average of 7.00%
Net marginKept as profit
4.08%
▼ below its 5-yr average of 4.78%
Returns & efficiency How well does it use its money?
Return on equityProfit on shareholders' money
5.97%
▲ above its 5-yr average of 5.89%
Return on assetsProfit on everything it owns
2.81%
▼ below its 5-yr average of 2.87%
Return on investmentProfit on long-term capital
3.37%
▼ below its 5-yr average of 3.41%
Growth Is the business getting bigger?
Revenue — last 12 months
+16.3%
▲ growing
Revenue — 3 yr, a year
+9.6%
▲ growing
Revenue — 5 yr, a year
+6.3%
▲ growing
EPS — last 12 months
−23.4%
▼ shrinking
EPS — 5 yr, a year
−7.0%
▼ shrinking
Dividend — 3 yr, a year
0.0%
▲ growing
Book value — 5 yr, a year
+8.5%
▲ growing
Financial strength Can it pay its bills and debts?
Debt to equityBorrowings for every ₹1 of shareholders' money
0.51×
Current ratioShort-term assets for every ₹1 due within a year
1.62×
Quick ratioLike the current ratio, without inventory
1.12×
Interest coverOperating profit ÷ interest to pay
5.41×
Payout ratioShare of profit paid as dividend
19.97%
Per share What each share stands for
EPS (TTM)
₹22.17
Book value
₹447.78
Cash flow
₹51.70
Dividend
₹5.00
Revenue
₹542.10
The share price is 2.38× the book value behind each share.
Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.
All 107 metrics from the data provider
Valuation
P/E excluding extraordinary items, most recent fiscal year42.19
Current Dividend Yield - Common Stock Primary Issue, LTM0.47
Price to Book - most recent fiscal year2.36
P/E Basic excluding extraordinary items - TTM43.68
P/E including extraordinary items - TTM47.72
P/E excluding extraordinary items low, trailing 12 months14.28
Price to Tangible Book - most fiscal year5.60
Dividend Yield - 5 Year Average0.85
Price to sales - most recent fiscal year2.02
Dividend Yield - indicated annual dividend divided by closing price0.47
Price to Cash Flow per share - trailing 12 month20.41
P/E Normalized, most recent fiscal year38.48
P/E excluding extraordinary items high, trailing 12 months225.10
P/E excluding extraordinary items, most recent fiscal year quarter47.72
Price to sales - trailing 12 month1.95
Net Debt, LFY23,495.00
Per share
Dividend Per Share - 5 year average5.00
Cash Flow per share - trailing 12 month51.70
Cash Flow per share - most recent fiscal year52.73
EPS including extraordinary items - trailing 12 month22.17
EPS including extraordinary items - most recent fiscal year25.08
EBITD per share - trailing 12 month76.71
Revenue/share - trailing 12 month542.10
EPS excluding extraordinary items - trailing 12 month22.17
EPS Basic excluding extraordinary items - most recent fiscal year25.15
EPS Basic excluding extraordinary items - trailing 12 month22.23
Book value per share - most recent fiscal year447.72
Dividend per share - most recent fiscal year5.00
Revenue/share - most recent fiscal year521.08
EPS Normalized - most recent fiscal year27.49
Book value (tangible) per share - most recent fiscal year188.75
Dividends per share - trailing 12 month5.00
EPS excluding extraordinary items - most recent fiscal year25.08
Cash per share - most recent fiscal year79.86
Margins
Operating margin - trailing 12 month8.01
Gross Margin - 5 year average63.05
Operating margin - 1st historical fiscal year9.18
Operating Margin - 5 year average9.47
Net Profit Margin % - 1st historical fiscal year4.80
Gross Margin - 1st historical fiscal year62.00
Net Profit Margin % - trailing 12 month4.08
Net Profit Margin - 5 year average4.78
Pretax Margin - 5 year average7.00
Pretax margin - 1st historical fiscal year7.42
Pretax margin - trailing 12 month6.34
Free Operating Cash Flow/Revenue, 5 Year Average−1.47
Gross Margin - trailing 12 month67.77
Growth
EPS Change %, TTM over TTM−23.43
Revenue growth rate, 5 year6.31
EPS growth rate, 5 year−7.00
Revenue Change % - most recent quarter 1 year ago17.29
Growth rate% - dividend, 3 year0.00
Revenue/share (5 yr growth)6.36
Tangible Book Value, Total Equity, 5 Year CAGR10.55
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR−5.88
Capital Spending growth rate, 5 year22.40
Revenue Change %, TTM over TTM16.27
Growth rate% - Revenue, 3 year9.64
Book value per share growth rate, 5 year8.49
EPS Change % - most recent quarter 1 year ago−44.98
Net Profit Margin growth rate, 5 year−12.59
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR−4.31
Total Debt, 5 Year CAGR5.02
Financial strength
Net Interest coverage - most recent fiscal year5.41
Free Cash Flow - most recent fiscal year−3,018.00
LT debt/equity - most recent fiscal year0.47
Quick ratio - most recent fiscal year1.12
Payout ratio - trailing 12 month22.61
Current ratio - most recent fiscal year1.62
Total debt/total equity - most recent fiscal year0.51
Net Interest coverage - trailing 12 month3.45
Payout ratio - most recent fiscal year19.97
Returns & efficiency
Return on average equity - 5 year average5.89
Net Income/employee - trailing 12 month6,21,177.30
Revenue/employee - most recent fiscal year1,47,79,720.00
Return on investment - most recent fiscal year3.37
Return on average assets - most recent fiscal year2.81
Receivables turnover - most recent fiscal year7.59
Inventory turnover - most recent fiscal year2.62
Revenue/employee - trailing 12 month1,52,17,080.00
Return on average assets - 5 year average2.87
Net Income/employee - most recent fiscal year7,09,568.00
Asset turnover - most recent fiscal year0.59
Return on average equity - most recent fiscal year5.97
Return on investment - 5 year average3.41
Price & volume
Market Cap16,684.03
52 week Low Date9 Mar 2026
Price - 1 Day % Change−1.20
Relative (S&P500) price percent change - 13 week11.90
Avg trading volume last 10 days0.22
Price - 13 week price percent change8.76
Price - 52 week price percent change−2.47
Avg Trading Volume Last 3 months5.28
Price - 5 Day % Change5.54
Price % Change Month To Date19.97
Relative (S&P500) price percent change - 04 week23.44
52 week High Date21 Oct 2025
Price - 26 week price percent change23.07
PDATE23 Sep 2026
Price - YTD price percent change−1.43
Relative (S&P500) price percent change - 52 week7.01
NPRICE1,058.00
Relative (S&P500) price percent change - 26 week23.80
52 week Low786.05
52 week High1,184.80
Beta1.22
Relative (S&P500) price percent change - Year to Date12.26
Dividends & Corporate Events
Payouts to shareholders, splits and bonus issues, and company meetings — newest first.
₹5.00
₹5.00
- Dividend yield0.47%
- Payout ratio19.97%
- 5-year average dividend₹5.00 a share
- Latest dividend₹5.00 per share · 24 Jul 2026
Corporate calendar
- MeetingAnnual General Meeting
- MeetingPostal Ballot
- BoardQuarterly Results
- BoardQuarterly Results
- Dividend₹5.00 per share · 500% · Final dividend
- BoardAudited Results & Final Dividend
- BoardQuarterly Results
- BoardQuarterly Results
Show 11 older events
- MeetingAnnual General Meeting
- BoardQuarterly Results
- Dividend₹5.00 per share · 500% · Final dividend
- BoardAudited Results & Final Dividend
- BoardQuarterly Results
- MeetingAnnual General Meeting
- MeetingPostal Ballot
- Dividend₹5.00 per share · 500% · Final dividend
- MeetingPostal Ballot
- Dividend₹5.00 per share · 500% · Final dividend
- Dividend₹5.00 per share · 500% · Final dividend
About Jubilant Pharmova
Biotechnology & Drugs
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals, including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical businesses working to address unmet medical needs in oncology and autoimmune diseases.
Key people
- Hari Shanker BhartiaNon-Executive Co-Chairman of the Board
- Ashish MukkirwarChief Financial Officer
- Naresh KapoorCompliance Officer, Company Secretary
- Arjun Shanker BhartiaJoint Managing Director, Executive Director
- Priyavrat BhartiaManaging Director, Executive Director
Company facts
- NSE symbolJUBLPHARMA
- BSE code530019
- ISININE700A01033
- IndustryBiotechnology & Drugs
- IndexNIFTY 500
- Market cap₹16,866 Cr
- Revenue (FY26)₹8,280 Cr
- Net profit (FY26)₹399 Cr
In the News
Recent headlines about Jubilant Pharmova — they open on Mint in a new tab.
- Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today - 16 July 2026
The Indian stock market ended Wednesday's session on a higher note. Sumeet Bagadia of Choice Broking recommends five breakout stocks to buy today.
16 Jul 2026 · 6 min read · Mint ↗ - The most undervalued CDMO stocks in India to watch
Within pharma, the CDMO segment is touted as the fastest-growing. Here are some undervalued companies in this space to track.
8 Apr 2026 · 5 min read · Mint ↗
Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →
Frequently Asked Questions
Jubilant Pharmova (NSE: JUBLPHARMA) last traded at ₹1,064.55 on the NSE, up 0.43% (₹4.56) on the day, as of 24 Sep 2026, 9:43 AM. On the BSE it was ₹1,063.20. The day's range was ₹1,038.05 – ₹1,067.30.
Jubilant Pharmova's 52-week high is ₹1,183.90 (21 Oct 2025) and its 52-week low is ₹783.75 (9 Mar 2026). At ₹1,064.55 the share is 10.1% below its high and 35.8% above its low.
Jubilant Pharmova's market capitalisation is ₹16,866 Cr (₹16,866 Cr). It is part of the NIFTY 500 index.
Jubilant Pharmova's P/E ratio (trailing 12 months) is 43.68. The sector average is 36.50, so investors pay 20% more for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹22.17.
Jubilant Pharmova shares are down 2.47% over the last year, down 1.43% so far this year, up 23.07% over 6 months, up 8.76% over 3 months. Over the last year the stock did 7.01% better than the market.
In FY26 (year to Mar 2026), Jubilant Pharmova reported revenue of ₹8,280 Cr (up 14.45% on the year before) and a net profit of ₹399 Cr. Earnings per share were ₹25.08.
Yes. Jubilant Pharmova's latest dividend is ₹5.00 per share (500%, final dividend), with an ex-date of 24 Jul 2026. The dividend yield is 0.47%. It has paid 5 dividends in the records shown on this page.
Of 3 analysts covering Jubilant Pharmova, 2 are bullish (1 strong buy, 1 buy), 0 say hold and 1 are bearish. The consensus is Buy (average rating 2.33 on a scale where 1 is Strong Buy and 5 is Strong Sell). Analyst views are opinions, not a guarantee.
As of Jun 2026: Promoter 47.68%, FII 15.87%, MF 8.99%, Other 27.46%.
Jubilant Pharmova's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.